vs
ADMA BIOLOGICS, INC.（ADMA）与WSFS FINANCIAL CORP（WSFS）财务数据对比。点击上方公司名可切换其他公司
WSFS FINANCIAL CORP的季度营收约是ADMA BIOLOGICS, INC.的2.0倍（$275.3M vs $139.2M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 31.5%，领先4.0%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 7.5%），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 1.7%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
WSFS金融集团是一家金融服务企业，核心子公司WSFS银行是总部位于特拉华州及大特拉华谷地区规模最大、经营历史最久的本地管理银行与财富管理机构。集团共运营115个网点，其中88个为银行网点，分布在宾夕法尼亚、特拉华、新泽西、佛罗里达、弗吉尼亚、内华达六州，提供全面金融服务。
ADMA vs WSFS — 直观对比
营收规模更大
WSFS
是对方的2.0倍
$139.2M
营收增速更快
ADMA
高出10.9%
7.5%
净利率更高
ADMA
高出4.0%
31.5%
两年增速更快
ADMA
近两年复合增速
1.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $275.3M |
| 净利润 | $49.4M | $86.8M |
| 毛利率 | 63.8% | — |
| 营业利润率 | 45.1% | — |
| 净利率 | 35.5% | 31.5% |
| 营收同比 | 18.4% | 7.5% |
| 净利润同比 | -55.9% | 31.7% |
| 每股收益（稀释后） | $0.20 | $1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAWSFS
| Q1 26 | — | $275.3M | ||
| Q4 25 | $139.2M | $271.9M | ||
| Q3 25 | $134.2M | $270.5M | ||
| Q2 25 | $122.0M | $267.5M | ||
| Q1 25 | $114.8M | $256.1M | ||
| Q4 24 | $117.5M | $261.5M | ||
| Q3 24 | $119.8M | $267.7M | ||
| Q2 24 | $107.2M | $266.0M |
净利润ADMAWSFS
| Q1 26 | — | $86.8M | ||
| Q4 25 | $49.4M | $72.7M | ||
| Q3 25 | $36.4M | $76.4M | ||
| Q2 25 | $34.2M | $72.3M | ||
| Q1 25 | $26.9M | $65.9M | ||
| Q4 24 | $111.9M | $64.2M | ||
| Q3 24 | $35.9M | $64.4M | ||
| Q2 24 | $32.1M | $69.3M |
毛利率ADMAWSFS
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — |
营业利润率ADMAWSFS
| Q1 26 | — | — | ||
| Q4 25 | 45.1% | 35.8% | ||
| Q3 25 | 38.0% | 37.3% | ||
| Q2 25 | 35.1% | 35.7% | ||
| Q1 25 | 30.4% | 34.0% | ||
| Q4 24 | 32.6% | 32.3% | ||
| Q3 24 | 33.1% | 31.9% | ||
| Q2 24 | 36.6% | 34.0% |
净利率ADMAWSFS
| Q1 26 | — | 31.5% | ||
| Q4 25 | 35.5% | 26.7% | ||
| Q3 25 | 27.1% | 28.3% | ||
| Q2 25 | 28.1% | 27.0% | ||
| Q1 25 | 23.4% | 25.7% | ||
| Q4 24 | 95.2% | 24.6% | ||
| Q3 24 | 30.0% | 24.1% | ||
| Q2 24 | 29.9% | 26.0% |
每股收益（稀释后）ADMAWSFS
| Q1 26 | — | $1.64 | ||
| Q4 25 | $0.20 | $1.33 | ||
| Q3 25 | $0.15 | $1.37 | ||
| Q2 25 | $0.14 | $1.27 | ||
| Q1 25 | $0.11 | $1.12 | ||
| Q4 24 | $0.45 | $1.08 | ||
| Q3 24 | $0.15 | $1.08 | ||
| Q2 24 | $0.13 | $1.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | — |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $2.7B |
| 总资产 | $624.2M | $22.1B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMAWSFS
| Q1 26 | — | — | ||
| Q4 25 | $87.6M | $1.7B | ||
| Q3 25 | $61.4M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $71.6M | — | ||
| Q4 24 | $103.1M | $1.2B | ||
| Q3 24 | $86.7M | — | ||
| Q2 24 | $88.2M | — |
总债务ADMAWSFS
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ADMAWSFS
| Q1 26 | — | $2.7B | ||
| Q4 25 | $477.3M | $2.7B | ||
| Q3 25 | $431.2M | $2.8B | ||
| Q2 25 | $398.3M | $2.7B | ||
| Q1 25 | $373.4M | $2.7B | ||
| Q4 24 | $349.0M | $2.6B | ||
| Q3 24 | $231.9M | $2.7B | ||
| Q2 24 | $188.3M | $2.5B |
总资产ADMAWSFS
| Q1 26 | — | $22.1B | ||
| Q4 25 | $624.2M | $21.3B | ||
| Q3 25 | $568.7M | $20.8B | ||
| Q2 25 | $558.4M | $20.8B | ||
| Q1 25 | $510.6M | $20.5B | ||
| Q4 24 | $488.7M | $20.8B | ||
| Q3 24 | $390.6M | $20.9B | ||
| Q2 24 | $376.4M | $20.7B |
负债/权益比ADMAWSFS
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | — |
| 自由现金流经营现金流 - 资本支出 | $34.6M | — |
| 自由现金流率自由现金流/营收 | 24.8% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | — |
8季度趋势，按日历期对齐
经营现金流ADMAWSFS
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $220.0M | ||
| Q3 25 | $13.3M | $121.5M | ||
| Q2 25 | $21.1M | $37.2M | ||
| Q1 25 | $-19.7M | $8.7M | ||
| Q4 24 | $50.2M | $219.9M | ||
| Q3 24 | $25.0M | $3.1M | ||
| Q2 24 | $45.6M | $44.8M |
自由现金流ADMAWSFS
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $213.6M | ||
| Q3 25 | $-1.1M | $120.3M | ||
| Q2 25 | $18.7M | $35.2M | ||
| Q1 25 | $-24.4M | $6.3M | ||
| Q4 24 | $47.5M | $205.6M | ||
| Q3 24 | $24.0M | $-489.0K | ||
| Q2 24 | $43.6M | $42.1M |
自由现金流率ADMAWSFS
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 78.6% | ||
| Q3 25 | -0.8% | 44.5% | ||
| Q2 25 | 15.3% | 13.2% | ||
| Q1 25 | -21.2% | 2.5% | ||
| Q4 24 | 40.4% | 78.6% | ||
| Q3 24 | 20.0% | -0.2% | ||
| Q2 24 | 40.7% | 15.8% |
资本支出强度ADMAWSFS
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 2.3% | ||
| Q3 25 | 10.7% | 0.5% | ||
| Q2 25 | 2.0% | 0.7% | ||
| Q1 25 | 4.1% | 0.9% | ||
| Q4 24 | 2.3% | 5.5% | ||
| Q3 24 | 0.9% | 1.4% | ||
| Q2 24 | 1.9% | 1.0% |
现金转化率ADMAWSFS
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 3.03× | ||
| Q3 25 | 0.36× | 1.59× | ||
| Q2 25 | 0.62× | 0.51× | ||
| Q1 25 | -0.73× | 0.13× | ||
| Q4 24 | 0.45× | 3.43× | ||
| Q3 24 | 0.70× | 0.05× | ||
| Q2 24 | 1.42× | 0.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
WSFS
暂无分部数据
